Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988027 | 1.00 | TACR1 (0.39) | TACR1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6991831 | 1.00 | TACR1 (0.39) | TACR1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6986957 | 0.94 | CNR1 (0.40) | TACR1MEN1KMT2AALDH1A1TRPM8 | |
| SCHEMBL6986953 | 0.94 | CNR1 (0.40) | TACR1MEN1KMT2AALDH1A1TRPM8 | |
| SCHEMBL6983809 | 0.88 | TACR1 (0.57) | TACR1GPBAR1 | |
| SCHEMBL6988800 | 0.88 | TACR1 (0.57) | TACR1GPBAR1 | |
| SCHEMBL6983798 | 0.88 | TACR1 (0.57) | TACR1GPBAR1 | |
| SCHEMBL6991143 | 0.83 | L3MBTL1 (0.48) | TACR1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6992945 | 0.79 | TACR1 (0.49) | TACR1GPBAR1 | |
| SCHEMBL6992940 | 0.79 | TACR1 (0.49) | TACR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0733632-B1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6489315-B1 | NOVEL CYCLIC COMPOUNDS HAVING AN EXCELLENT TACHYKININ RECEPTOR ANTAGONISTIC EFFECT, AND A METHOD FOR PRODUCING THEM, FOR TREATING DISORDERS OF INCONTINENCE, ASTHMA, MIGRAINE, IRRITABLE BOWEL SYNDROME, PAIN, COUGH OR EMESIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| CN-1291099-A | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1061926-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| WO-1999047132-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-23 | — | — | WO | disclosed |
| EP-0733632-A1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | TACR1 97/4885MEN1 669/4885KMT2A 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.